Home Cart Sign in  
Chemical Structure| 56-06-4 Chemical Structure| 56-06-4

Structure of 56-06-4

Chemical Structure| 56-06-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

2,4-Diamino-6-hydroxypyrimidine (DAHP) is a selective and specific inhibitor of GTP cyclohydrolase I, the rate limiting step for de novo pterin synthesis, with IC50 about 0.3 mM for inhibition of BH4 biosynthesis in HUVEC cells.

Synonyms: DAHP

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 2,4-Diamino-6-hydroxypyrimidine

CAS No. :56-06-4
Formula : C4H6N4O
M.W : 126.12
SMILES Code : O=C1N=C(N)NC(N)=C1
Synonyms :
DAHP
MDL No. :MFCD08528919
InChI Key :SWELIMKTDYHAOY-UHFFFAOYSA-N
Pubchem ID :135408763

Safety of 2,4-Diamino-6-hydroxypyrimidine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of 2,4-Diamino-6-hydroxypyrimidine

ferroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-453 cells 0.25–4 mM 24 h To investigate the effect of DAHP on IDO1 expression, results showed that DAHP downregulated IDO1 expression at concentrations as low as 0.5 mM after 3 h of supplementation. J Immunother Cancer. 2021 Jul;9(7):e002383.
BT549 cells 0.25–4 mM 24 h To investigate the effect of DAHP on IDO1 expression, results showed that DAHP downregulated IDO1 expression at concentrations as low as 0.5 mM after 3 h of supplementation. J Immunother Cancer. 2021 Jul;9(7):e002383.
Human foreskin fibroblasts 3–5 mM 7 days To evaluate the inhibitory effect of DAHP on Toxoplasma growth, results showed that high doses of DAHP slowed parasite growth, and this effect could be rescued by BH4 supplementation. Nat Microbiol. 2024 Sep;9(9):2323-2343.
human umbilical vein endothelial cells (HUVECs) 10 nM 6 h FAM3D caused eNOS uncoupling and reduced NO production Cell Rep Med. 2023 Jun 20;4(6):101072.
IGROV1 cells 0.55 nM 96 h Evaluate the antiproliferative activity of compound 3 toward IGROV1 cells, showing an IC50 of 0.55 nM J Med Chem. 2011 Oct 27;54(20):7150-64.
KB cells 0.26 nM 96 h Evaluate the antiproliferative activity of compound 3 toward KB cells, showing an IC50 of 0.26 nM J Med Chem. 2011 Oct 27;54(20):7150-64.
CHO cells 0.31 nM 96 h Evaluate the antiproliferative activity of compound 3 toward FR α-expressing cells, showing an IC50 of 0.31 nM J Med Chem. 2011 Oct 27;54(20):7150-64.
bovine aortic endothelial cells 10 mM 24 h reduced both total biopterins and BH4 levels, increased superoxide levels, decreased NO release Hypertension. 2008 Sep;52(3):484-90.
human endothelial progenitor cells (EPCs) 3 μM 24 h increased BH4 production and GTPCH I activity Hypertension. 2011 Aug;58(2):287-94.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice 4T1 cell-induced breast cancer model Oral 100 mg/kg Twice daily until the end of the experiment To investigate the effect of DAHP on tumor growth and the immune microenvironment, results showed that DAHP significantly inhibited tumor growth and enhanced the antitumor effect of PD-1 blockade immunotherapy. J Immunother Cancer. 2021 Jul;9(7):e002383.
Mice AngII-induced hypertensive model Administered in drinking water 10 mM For 14 days DAHP caused eNOS uncoupling by reducing intracellular BH4 and abolished the protective effect of FAM3D deficiency against AngII-induced hypertension Cell Rep Med. 2023 Jun 20;4(6):101072.
ICR SCID mice IGROV1 ovarian carcinoma model Intravenous administration 40 mg/kg Q4dx5 schedule, administered on days 3, 7, 11, 15, and 19 Evaluate the in vivo antitumor activity of compound 3 toward IGROV1 tumor model, showing T/C values of 14% and gross log kill values of 2.7 J Med Chem. 2011 Oct 27;54(20):7150-64.
Mice DAHP-induced pulmonary hypertension model Drinking water 10 mM 3, 6, and 9 weeks DAHP induces eNOS uncoupling by inhibiting GTP cyclohydrolase 1, leading to pulmonary hypertension phenotypes including increased mean pulmonary arterial pressure (mPAP) and right ventricular systolic blood pressure (RVSP), and pulmonary vascular remodeling. Circ Res. 2024 Feb 16;134(4):351-370
Wistar rats Myocardial ischemia and reperfusion injury model Intraperitoneal 200 mg/kg Single dose Inhibition of GTPCH-1, abolishing the cardioprotective effects of isoflurane preconditioning Anesthesiology. 2015 Sep;123(3):582-9
Nude mice Carotid artery injury model Injection after pretreatment of EPCs 3 µmol/L 24 hours pretreatment before injection Enhanced the ability of EPCs to repair injured endothelium Hypertension. 2011 Aug;58(2):287-94.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

7.93mL

1.59mL

0.79mL

39.64mL

7.93mL

3.96mL

79.29mL

15.86mL

7.93mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories